HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.

Abstract
Previous studies from our laboratory using complement-mutant mice demonstrated that the alternative pathway is the dominant activation pathway responsible for complement-mediated pathology in demyelinating disease. Using a well-characterized inhibitory monoclonal antibody (mAb 1379) directed against mouse factor B, we assessed the therapeutic value of inhibiting the alternative complement pathway in experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis. Administration of anti-factor B antibody to mice prior to the onset of clinical signs of active EAE had no affect on the onset or acute phase of disease, but significantly attenuated the chronic phase of disease resulting in reduced cellular infiltration, inflammation and demyelination in antibody-treated mice. Attenuation of the chronic phase of disease was long lasting even though antibody administration was terminated shortly after disease onset. Chronic disease was also attenuated in transferred EAE when anti-factor B antibody was administered before or after disease onset. Similar levels of disease attenuation were observed in transferred EAE using MOG-specific encephalitogenic T cells. These studies demonstrate the therapeutic potential for inhibition of factor B in the chronic phase of demyelinating disease, where treatment options are limited.
AuthorsXianzhen Hu, V Michael Holers, Joshua M Thurman, Trent R Schoeb, Theresa N Ramos, Scott R Barnum
JournalMolecular immunology (Mol Immunol) Vol. 54 Issue 3-4 Pg. 302-8 (Jul 2013) ISSN: 1872-9142 [Electronic] England
PMID23337717 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2013 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Complement System Proteins
  • Complement Factor B
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, pharmacology)
  • Complement Factor B (classification)
  • Complement Pathway, Alternative (drug effects, immunology)
  • Complement System Proteins (immunology)
  • Demyelinating Diseases (immunology)
  • Disease Models, Animal
  • Encephalomyelitis, Autoimmune, Experimental (drug therapy, immunology)
  • Inflammation (immunology)
  • Mice
  • Mice, Inbred C57BL
  • T-Lymphocytes (drug effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: